Eli Lilly and Company (ETR:LLY)
Germany · Delayed Price · Currency is EUR | Market Cap | 908.71B +55.6% |
| Revenue (ttm) | 62.66B +47.4% |
| Net Income | 21.92B +127.6% |
| EPS | 24.42 +129.1% |
| Shares Out | n/a |
| PE Ratio | 41.45 |
| Forward PE | 32.64 |
| Dividend | 5.52 (0.54%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 706 |
| Open | 1,018.60 |
| Previous Close | 1,022.80 |
| Day's Range | 1,004.80 - 1,044.80 |
| 52-Week Range | 535.80 - 1,090.80 |
| Beta | 0.51 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Lilly's Next-Generation Obesity Shot Clears Another Hurdle
Eli Lilly & Co.'s next-generation weight-loss shot retatrutide didn't increase overall heart risk in a new study, helping dispel concerns over its potential. The company plans to file for US Food and ...
Eli Lilly Will File For Retatrutide Approval—As Study Shows Average Weight Loss Of 56 Pounds
Analysts have suggested retatrutide could become a blockbuster weight loss drug if approved. In January, TD Cowen analysts estimated retatrutide could generate $3.8 billion in sales in 2030, while Glo...
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.
Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application
Eli Lilly on Thursday said two more Phase 3 trials of its experimental obesity drug retatrutide showed positive results and it plans to submit an application to the U.S. Food and Drug Administration ...
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
Eli Lilly said it will file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, as it succeeds in two more late-stage trials. The drug delivered significant w...
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults ...
Weight loss drugs linked to increase risk of hair loss
Weight loss drugs such as Mounjaro, Ozempic and Wegovy are linked to an increased risk of hair loss, according to researchers.
Hair loss with GLP-1 drugs is rare, but real, studies find
The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest.
Lilly confirms date and conference call for second-quarter 2026 financial results announcement
INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call that ...
Many US patients opt for obesity drug injections, defying some expectations
Many patients have opted for injectable forms of the wildly popular GLP-1 obesity medications through a pilot program of the U.S. government's Medicare health insurance program for Americans aged 65 ...
Trump says generic drugs to face no US tariffs for 2 years before rates of 100% and 200% later
President Donald Trump said on Tuesday all generic drugs being brought into the U.S. will continue having a tariff of 0% for two years starting from August 1, after which the tariff rate wi...
Novo Nordisk Sues Eli Lilly Over Weight-Loss Drug Advertising
Novo Nordisk alleges Eli Lilly falsely advertised Zepbound and Mounjaro by claiming the drugs outperform Wegovy and Ozempic.
Novo Sues Rival Lilly Over Weight-Loss Ads
Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls are misleading ads about obesity drugs in the US. Novo says Lilly is using outdated information when comparing Novo'...
Cramer's Mad Dash: Eli Lilly
CNBC's Jim Cramer delivers his daily Mad Dash.
Novo Nordisk Sues GLP-1 Rival Eli Lilly For Misleading Advertising
Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, accusing the company of using “intentionally selected outdated studies” to curate allegedly misleading ...
Novo Nordisk sues Eli Lilly over weight-loss drug advertising claims
Novo Nordisk has filed a lawsuit against Eli Lilly (LLY) in a US federal court, accusing its rival of running false and misleading advertising campaigns for its blockbuster diabetes and weight-loss dr...
Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications
The drugmaker says Lilly isn't including the most up-to-date clinical information about its drugs
Novo Nordisk filed a lawsuit against rival Eli Lilly accusing it of using outdated studies to promote its GLP-1 drugs
The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.
Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising
Novo Nordisk said on Tuesday it was suing rival Eli Lilly in U.S. federal court, accusing the U.S. drugmaker of false advertising in claiming its weight-loss medicines outperform Novo's drugs.
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo Nordisk filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed to mislead consumers about their superior efficacy r...
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
Thursday's announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma's increasing embrace of a long-stigmatized cla...
One in Every Five U.S. Homes Using GLP-1s: What it Means for Consumer Trends
MichaelAaron Flicker examines the growing impact of GLP-1 medications on consumer behavior, noting that roughly one in five American households has someone using a GLP-1 drug. He explains how that tre...
Looking to diversify away from AI trade? Buy these 3 stocks
For investors seeking to pare exposure to the artificial intelligence (AI) trade amid boom-induced volatility, shifting capital toward overlooked equities offers a compelling strategic alternative. Ma...
AtaiBeckley stock is soaring, and it has Eli Lilly to thank
AtaiBeckley (ATAI) shares are ripping higher on Thursday morning after pharmaceutical giant Eli Lilly (LLY) said it will acquire the clinical-stage biotechnology firm for up to $3.8 billion. Lilly has...